| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| May 6, 2026 | ±3.1% | -8.6% | under-priced |
| November 4, 2025 | ±1.9% | +6.0% | under-priced |
| August 5, 2025 | ±2.5% | +1.6% | over-priced |
| May 6, 2025 | ±3.0% | -9.3% | under-priced |
| November 1, 2024 | ±1.9% | -5.1% | under-priced |
| August 2, 2024 | ±2.1% | -5.1% | under-priced |
| May 3, 2024 | ±2.0% | +3.8% | under-priced |
| November 7, 2023 | ±2.5% | +0.0% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $0.61 | $1.9B | $466M |
| Q4 FY2025 | $0.48 | $2.0B | $368M |
| Q3 FY2025 | $0.42 | $1.8B | $322M |
| Q2 FY2025 | $0.67 | $2.0B | $511M |
CTRA (CTRA) reports in 99 days, with the next report estimated for September 20, 2026. Across the last 8 reports, options priced an average ±2.4% earnings move while the stock actually moved 4.9% on average — the market has tended to under-price CTRA's earnings risk. Fundamentals into the print: EPS down 10.3% year-over-year, revenue up 2.3%.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →